Microvascular Therapeutics Secures Investment from Utah’s Nucleus Fund

Microvascular Therapeutics Inc. (MVT), a biotechnology company developing next-generation ultrasound contrast and theranostic agents, has received an investment from Utah’s state-backed Nucleus Fund.

The investment was unanimously approved by the fund’s investment committee and executed through MVT’s convertible note. 

For MVT, the investment marks a significant milestone.

“This is our first institutional investor,” said Dr. Evan Unger, CEO and Founder of MVT. “Their support is a strong validation of our technology and opportunity following Nucleus’ extensive due diligence.” 

Nucleus Fund leaders emphasized both the strength of the company’s science and the experience of its founder as key drivers behind the partnership.

“We were drawn to MVT by Dr. Unger’s track record and the transformative potential of their technology,” said Kristin Wihera, Director of Fund Operations. She noted that the fund conducted a detailed due diligence process and will continue to follow the company’s development as it grows in Utah and beyond.

A New Frontier for Ultrasound Contrast

Microvascular Therapeutics is focused on advancing ultrasound contrast and theranostic technologies that could reshape both cardiovascular and oncology imaging and treatment. Its lead product, MVT-100, is designed to improve the safety, performance, and accessibility of ultrasound contrast worldwide.

About the Nucleus Fund

The Nucleus Fund, formerly the Utah Innovation Fund, is Utah’s state-backed early-stage investment vehicle dedicated to supporting high-potential deep-tech companies. Operated by the Nucleus Institute, the fund provides capital and applied commercialization resources to help founders accelerate innovation and scale in Utah’s growing technology ecosystem.